Ignite Creation Date:
2025-12-24 @ 6:57 PM
Ignite Modification Date:
2026-01-23 @ 2:54 AM
Study NCT ID:
NCT03032757
Status:
UNKNOWN
Last Update Posted:
2017-10-25
First Post:
2017-01-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lysosomal Movement and Anabolic Resistance
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D055948', 'term': 'Sarcopenia'}], 'ancestors': [{'id': 'D009133', 'term': 'Muscular Atrophy'}, {'id': 'D020879', 'term': 'Neuromuscular Manifestations'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D001284', 'term': 'Atrophy'}, {'id': 'D020763', 'term': 'Pathological Conditions, Anatomical'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000601', 'term': 'Amino Acids, Essential'}], 'ancestors': [{'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 26}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2017-05-12', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-10', 'completionDateStruct': {'date': '2018-08-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-10-24', 'studyFirstSubmitDate': '2017-01-19', 'studyFirstSubmitQcDate': '2017-01-25', 'lastUpdatePostDateStruct': {'date': '2017-10-25', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-01-26', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2018-08-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Lysosomal movement', 'timeFrame': '~360 minutes', 'description': 'Changes in intracellular localization of lysosomes will be measured via immunofluorescence'}], 'secondaryOutcomes': [{'measure': 'Lysosomal movement in isolated muscle cells', 'timeFrame': '~30 minutes', 'description': 'Changes in intracellular localization of lysosomes will be measured via immunofluorescence'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Sarcopenia']}, 'descriptionModule': {'briefSummary': 'Age-associated loss of muscle mass, termed sarcopenia, is strongly associated with functional impairment and physical disability in the elderly. Maintenance or growth of muscle mass is mainly driven by increased muscle protein synthesis (i.e. the generation of new muscle protein) in response to exercise and feeding. However, several investigations have shown that elderly individuals have a blunted protein synthetic response following protein intake. This inability of the elderly to properly respond to growth stimuli has been termed anabolic resistance and plays a significant role in the development of sarcopenia. However, the precise mechanisms underpinning anabolic resistance are unknown.\n\nIt is well established that muscle protein synthesis at the molecular level is regulated by a cellular protein complex called mTORC1. When exposed to a growth stimulus, mTORC1 has been shown to associate with lysosomes, i.e. the intracellular organelles responsible for the breakdown of cellular proteins, and subsequently moving towards the cell periphery.\n\nThis movement of lysosome-associated mTORC1 within the cell is believed to be vital for the activation of protein synthesis, as inhibition of lysosomal movement blunts mTORC1 activation in response to amino acids. Thus, dysregulation of lysosomal movement in ageing muscle may represent an underlying mechanism in the development of anabolic resistance. However, this area of research is unexplored in the context of human skeletal muscle. The investigators hypothesize that dysregulation of lysosomal movement plays a central role in the development of age-associated skeletal muscle anabolic resistance.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\nBe a non-smoking male within the specified age range for each group (young; 18-35 yrs, old; 65-75 yrs)\n\nHave a BMI (body mass index, body weight/height in m2) between 18 and 25 kg/m2, which is considered a normal body mass index.\n\nBe in good general health: no cardiovascular diseases or metabolic diseases.\n\nExclusion Criteria:\n\nHealth problems such as: heart disease , metabolic disease such as phenylketonuria, rheumatoid arthritis, uncontrolled hypertension, poor lung function, or any health condition that might put the participant at risk when participating in this study.\n\nGeneralized neuromuscular disease (such as Parkinson's disease or motorneuron disease).\n\nInvolvement in regular structured resistance exercise training at the time of the study.\n\nConsumption of any analgesic drugs, anti-inflammatory drugs, or medication that is known to affect protein metabolism (beta-blockers, corticosteroids, NSAIDs).\n\nParticipants who have undergone muscle biopsy testing or isotope infusion procedures within the last 5 years.\n\nAllergic to lidocaine"}, 'identificationModule': {'nctId': 'NCT03032757', 'briefTitle': 'Lysosomal Movement and Anabolic Resistance', 'organization': {'class': 'OTHER', 'fullName': 'University of Birmingham'}, 'officialTitle': 'Defining the Role of Lysosomal Movement in Age-associated Anabolic Resistance in Human Skeletal Muscle', 'orgStudyIdInfo': {'id': 'RG_16-200'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Resting leg of young males', 'interventionNames': ['Dietary Supplement: Essential amino acids']}, {'type': 'EXPERIMENTAL', 'label': 'Exercising leg of young males', 'interventionNames': ['Dietary Supplement: Essential amino acids']}, {'type': 'EXPERIMENTAL', 'label': 'Resting leg of elderly males', 'interventionNames': ['Dietary Supplement: Essential amino acids']}, {'type': 'EXPERIMENTAL', 'label': 'Exercising leg of elderly males', 'interventionNames': ['Dietary Supplement: Essential amino acids']}], 'interventions': [{'name': 'Essential amino acids', 'type': 'DIETARY_SUPPLEMENT', 'description': '240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.', 'armGroupLabels': ['Exercising leg of elderly males', 'Exercising leg of young males', 'Resting leg of elderly males', 'Resting leg of young males']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'B152TT', 'city': 'Birmingham', 'state': 'West Midlands', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'William Apro, Ph.D.', 'role': 'CONTACT', 'email': 'w.apro@bham.ac.uk', 'phone': '0121 414 2875'}], 'facility': 'School of Sport, Exercise and Rehabilitation Sciences at University of Birmingham', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}], 'centralContacts': [{'name': 'William Apro, Ph.D.', 'role': 'CONTACT', 'email': 'w.apro@bham.ac.uk', 'phone': '01214142875'}, {'name': 'Andrew Philp, Ph.D.', 'role': 'CONTACT', 'email': 'a.philp@bham.ac.uk', 'phone': '0121414 8872'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Birmingham', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Ph.D.', 'investigatorFullName': 'William Apro', 'investigatorAffiliation': 'University of Birmingham'}}}}